Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients



Status:Active, not recruiting
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:March 5, 2015
End Date:March 2023

Use our guide to learn which trials are right for you!

Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)

A study to evaluate changes over time in renal function from baseline (time of conversion) up
until five years post conversion in kidney transplant patients converted from tacrolimus
twice daily (BD) formulations to a once daily formulation as Advagraf.

This is a multicenter long-term (up to five years post-conversion), non-interventional
registry in kidney transplant patients who have been converted from tacrolimus BD to
Advagraf. Centers that are providing medical care for kidney transplant patients who may
convert patients from tacrolimus BD to Advagraf will be identified and requested to approach
patients for consent to participate.

Inclusion Criteria:

- Adult kidney transplant patients who are on tacrolimus BD and identified for
conversion to Advagraf. Patients will only be approached about participating in the
registry after their physician has made the decision to convert them to Advagraf.
Patients previously treated with Advagraf and who have stopped for any reason will not
be excluded from the registry provided that the physician has decided to convert.

Exclusion Criteria:

- Patients currently taking Advagraf treatment
We found this trial at
2
sites
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials